ENTRY       D09967                      Drug
NAME        Secukinumab (USAN/INN);
            Secukinumab (genetical recombination) (JAN);
            Cosentyx (TN)
PRODUCT     COSENTYX (Novartis Pharmaceuticals Corporation)
FORMULA     C6584H10134N1754O2042S44
EXACT_MASS  147851.0774
MOL_WEIGHT  147942.2994
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMNWVRQA PGKGLEWVAA INQDGSEKYY
            VGSVKGRFTI SRDNAKNSLY LQMNSLRVED TAVYYCVRDY YDILTDYYIH YWYFDLWGRG
            TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF
            PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP
            APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK
            PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT
            LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL
            TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (Light chain)
            EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY GASSRATGIP
            DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPCTFG QGTRLEIKRT VAAPSVFIFP
            PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
            TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
            (Disulfide bridge: H22-H96, H154-H210, H271-H331, H377-H435, H236-H'236, H239-H'239, L23-L89, L135-L195, H230-L215)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AC10
            Product: D09967<JP/US>
EFFICACY    Antipsoriatic, Anti-IL-17A antibody
  DISEASE   Plaque psoriasis [DS:H01656]
            Psoriatic arthritis [DS:H01507]
            Ankylosing spondylitis [DS:H01674]
  TYPE      Monoclonal antibody
TARGET      IL17A [HSA:3605] [KO:K05489]
  PATHWAY   hsa04060(3605)  Cytokine-cytokine receptor interaction
            hsa05323(3605)  Rheumatoid arthritis
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC10 Secukinumab
                  D09967  Secukinumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunological Agents, Other
               Interleukin Blockers
                Secukinumab
                 D09967  Secukinumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D09967  Secukinumab (USAN/INN); Secukinumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09967  Secukinumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D09967  Secukinumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Interleukins
                IL17A
                 D09967  Secukinumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09967
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D09967
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D09967
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09967
DBLINKS     CAS: 1229022-83-6
            PubChem: 124490635
///
